Quimioterapia adyuvante asociada a hormonoterapia en mujeres postmenopáusicas con cáncer de mama subtipo Luminal A en estadio temprano: análisis comparativo de la supervivencia global

• Autores: Carranza Neira, Julia Alejandra, Díaz Subauste, Roxana Sofía, Roig Tupayachi, Silvana Patricia
• Formato: tesis de grado
• Fecha de Publicación: 2015
• Institución: Universidad Peruana de Ciencias Aplicadas
• Repositorio: UPC-Institucional
• Lenguaje: español
• OAI Identifier: oai:repositorioacademico.upc.edu.pe:10757/621762
• Enlace del recurso: http://hdl.handle.net/10757/621762
• Nivel de acceso: acceso abierto
• Materia: Quimioterapia adyuvante; Neoplasias de la mama; Análisis de supervivencia; Receptores estrogénicos; Receptores de progesterona; Adjuvant chemotherapy; Breast cáncer; Estrogen receptor; Progesterone receptor; Overall survival; Perú

Purpose: to evaluate if there is a difference between adjuvant chemo-endocrine therapy (QHT) and hormone therapy (HT) alone in ten years overall survival (OS) in post-menopausal women with early stage luminal A breast cancer Methods: A non concurrent cohort study was conducted in a cancer treatment center in Peru, we measured demographic and clinical-pathologic anatomy variables. Log-rank test and a Kaplan-Meier (KM) curve were performed to evaluate ten years OS. Cox regression analysis was used and hazard ratio were reported with confidence intervals 95% (95%CI) for crude and adjusted by the significant variables in the bivariate analysis. The fullfilment of hazard proportionality was evaluated by Schoenfeld residuals method and graphic method. Results: 65 patients received adjuvant chemo-endocrine therapy and 140 only received hormone therapy. Ten years OS was 77% for QHT and 84% for HT, this difference was not significant when using KM and log-rank; age at diagnosis (p=0,01), clinical status (p=0,02), tumor size (p=0,04), positive estrogen receptor (p=0,03), node status (p=0,012) and type of surgery (p=0,03) were statistically significant when compare with OS. When proportional hazards assumption was evaluated (SPH), only the period of time after two years of following was satisfied, cox models were created for this period of time. Crude HR for ten years OS was 1,48 (CI95%:0,65-3,39). First model adjusted HR was 1,83 (CI95%:0,64-5,30) and second model adjusted HR was 1,77 (CI95%:0,64-4,90). Conclusions: There was no significant difference in ten years OS between both courses of treatment evaluated in post-menopausal women with luminal A breast cancer.